JCO: CAR-T treatment of Hodgkin's lymphoma shows positive results.

A recent clinical trial published in journal Clinical Oncology showed that CAR-T therapy successfully treated Hodgkin's lymphoma (Hodgkin lymphoma, HL).
researchers demonstrated in the study that the treatment was safe and effective in patients with recurrent/refractive Hodgkin's lymphoma.
most patients completely disappear edified tumors at the highest dose of treatment, and almost all patients have clinical benefits after treatment.
DOI: Car-T therapy has been a surprising success in a number of clinical trials over the past decade, and has been approved by the U.S. Food and Drug Administration to treat both acute lymphocytic leukemia and diffuse large B-cell lymphoma, and two CAR-T products have been listed for CD19 antigens with high expression on the surface of B-cell malignancies.
inspired by the success of CAR-T cell therapy in treating these cancers, researchers have been developing techniques to express other cancer-related proteins. Dr. Barbara Savoldo, a professor in the Department of Microbiology and Immunology at unC University, and his colleagues have been exploring ways to combat Hodgkin's lymphoma using CAR-T in recent years.

Hodgkin's lymphoma is one of the most common malignant blood tumors in young people.
the application of modern chemotherapy has made Hodgkin's lymphoma a curable tumor, but the follow-up results of a large number of long-term survival patients show that the disease is highly susceptible to recurrence and can induce a second tumor (solid tumor and acute non-lymphocytic leukemia), as well as other diseases (acute myocardial infarction, pulmonary fibrosis, etc.).
, chemotherapy can also cause infertility and deformities.
2017, the Savoldo team found that CAR-T treatment for The Dukkin cell-related protein CD30 appeared to be safe, but produced only a moderate response, in a preliminary study published by Savoldo team on seven patients with refracted/recurrent Hodgkin's lymphoma.
UNC Lineberger's Barbara Savoldo, MD, PhD in the new study (NCT02690545/NCT02917083), the researchers used the same anti-CD30CAR-T strategy for 41 patients, but added a pretreatment regimen - using drugs such as cyclophosphamide and fluorine before CAR-T cell infusion.
" this scenario seems to provide a more favorable environment for CAR-T cells to multiply and attack cancer cells.
," said Dr. Natalie Grover, assistant professor of medicine at UNC.
of the 41 patients treated, the researchers observed 10 cases of CRS, all of which were level 1, with no neurotoxicity observed.
total remission rate was 72% in 32 patients with active disease who received fludadarabin-based lymph node removal removal, of which 19 (59%) were completely remissioned.
an average follow-up of 533 days, and the one-year progressless survival and total survival of all assessable patients were 36% (95% CI, 21%-51%) and 94% (95% CI, 79%-99%) respectively. The amplification of CAR-T cells in
depends on the cell dose.
this data suggests that this anti-CD30 CAR-T therapy appears to be very effective even for refractive/recurrent Hodgkin's lymphoma.
in general, the researchers believe that patients with severe recurrent or refractive HL have a high long-lasting response rate after receiving lymphatic severation and CD30 CAR-T therapy, and that the safety is excellent, highlighting the feasibility of extending CAR-T cell therapy beyond conventional B-cell malignancies.
future, researchers plan to conduct further research into CAR-T therapy, either individually or in conjunction with other immunomodulatory anticancer drugs.
References: 1. Excellent research results for CAR-T Cell therapy st Hodgkin lymphoma2. Anti-CD30 CAR-T CellTherapy in Relapsed y Refractory Hodgkin Lymphoma.